determin
accuraci
poc
immunoassay
identifi
clinic
signific
immun
respons
viral
andor
bacteri
infect
sixti
patient
acut
febril
respiratori
infect
pharyng
lower
respiratori
tract
infect
lrti
enrol
particip
provid
fingerstick
blood
immunoassay
test
myxoviru
mxa
creactiv
protein
crp
four
oropharyng
sampl
viral
pcr
routin
bacteri
cell
cultur
aven
blood
sampl
collect
elisawa
use
measur
crp
mxa
pair
serolog
test
use
confirm
atyp
bacteria
urin
sampl
provid
streptococcu
legionella
antigen
test
patient
suspect
lrti
sputum
blood
cultur
chest
xray
wbc
count
measur
viral
infect
confirm
oropharyng
pcr
posit
viral
pathogen
bacteri
infect
confirm
posit
throat
sputum
cultur
elev
immunoglobulin
antibodi
twofold
increas
igg
antibodi
acut
convalesc
phase
indic
atyp
bacteria
posit
streptococcu
legionella
urin
antigen
assay
also
confirm
bacteri
infect
immunoassay
correctli
categor
subject
neg
bacteri
infect
viral
infect
conclus
interplay
mxa
valu
semiquantit
crp
valu
aid
differenti
infecti
etiolog
isol
neither
mxa
crp
alon
sensit
specif
howev
pattern
result
rapid
immunoassay
provid
sensit
specif
method
differenti
acut
febril
respiratori
infect
diagnost
inform
may
help
reduc
antibiot
misus
resist
lower
healthcar
cost
v
iral
bacteri
respiratori
infect
repres
major
sourc
morbid
mortal
healthcar
cost
accord
center
diseas
control
prevent
cdc
antimicrobi
resist
one
seriou
health
threat
face
unit
state
approxim
antimicrobi
prescrib
primari
care
respiratori
tract
indic
mani
indic
antibiot
unlik
provid
clinic
benefit
patient
major
antibiot
prescrib
adult
ambulatori
practic
unit
state
attribut
lack
clinic
differenti
featur
although
untreat
bacteri
infect
may
caus
seriou
complic
treat
viral
ill
noninfect
caus
inflamm
antibiot
ineffect
also
contribut
develop
resist
increas
cost
risk
antibiot
allergi
andor
toxic
antibioticresist
infect
add
nearli
billion
excess
direct
healthcar
cost
unit
state
includ
addit
cost
societi
lost
product
may
high
billion
year
ideal
infecti
diseas
biomark
would
impact
health
threat
combin
diagnost
prognost
therapeut
followup
characterist
creactiv
protein
crp
acutephas
protein
normal
serum
concentr
less
mgl
increas
inflammatori
process
especi
follow
sever
infect
presenc
sever
infect
inflamm
crp
rise
mgl
bacteri
infect
potent
stimulu
mark
crp
elev
occur
within
h
infect
peak
h
follow
antibiot
treatment
crp
level
fall
rapidli
rise
crp
usual
correspond
extent
bacteri
infect
normal
crp
level
patient
symptom
respiratori
infect
like
indic
noninvas
selflimit
infect
requir
referr
hospit
antibiot
treatment
serum
crp
usual
elev
mgl
viral
infect
howev
invas
adenoviru
influenza
rais
crp
mgl
metaanalysi
studi
look
singl
valu
serum
crp
use
cutoff
bacteri
diseas
includ
gramposit
gramneg
bacteria
result
bimod
outcom
three
studi
recommend
crp
cutoff
valu
set
mgl
seven
studi
recommend
cutoff
mgl
myxoviru
resist
protein
mxa
deriv
interferon
alphabeta
cell
becom
elev
presenc
viral
infect
specif
particular
type
viru
mxa
low
basal
concentr
less
ngml
fast
induct
time
h
infect
long
halflif
day
mxa
peak
h
remain
elev
presenc
elev
interferon
mxa
protein
express
peripher
blood
shown
sensit
specif
marker
viral
infect
viral
infect
elev
mxa
level
modest
increas
crp
level
isol
neither
mxa
crp
alon
sensit
specif
identifi
viral
andor
bacteri
infect
review
sever
systemat
analys
crp
show
low
cutoff
valu
crp
demonstr
high
sensit
low
specif
detect
bacteri
infect
wherea
high
cutoff
valu
crp
show
low
sensit
high
specif
detect
bacteri
infect
mxa
specif
identifi
viral
infect
sensit
bacteri
infect
thu
simultan
examin
two
level
crp
mgl
serum
equival
mgl
serum
equival
combin
presenc
elev
level
mxa
ngml
possibl
enhanc
sensit
specif
crp
marker
interplay
semiquantit
valu
crp
mxa
help
identifi
patient
clinic
signific
underli
immun
respons
consist
suspect
respiratori
infect
patient
repres
microbiolog
unconfirm
respiratori
ill
muri
marker
also
simultan
aid
differenti
viral
bacteri
acut
febril
respiratori
infect
examin
togeth
pointofcar
poc
test
marker
provid
sensit
specif
mean
assess
clinic
signific
differenti
acut
febril
respiratori
infect
prospect
singl
center
blind
clinic
feasibl
trial
perform
beth
israel
deaco
medic
center
harvard
medic
school
teach
tertiari
care
hospit
decemb
august
feasibl
trial
plan
estim
minimum
sampl
size
enrol
neg
patient
confirm
viral
patient
confirm
bacteri
patient
studi
enrol
patient
male
femal
acut
febril
respiratori
infect
subject
older
year
age
present
fever
acut
respiratori
symptom
consist
infect
report
bodi
temperatur
last
h
consid
elig
studi
supplementari
file
enrol
case
subject
separ
two
group
presum
pharyng
presum
lrti
supplementari
file
patient
fever
asymptomat
describ
inclus
criteria
patient
consid
inclus
control
subject
supplementari
file
twentyfour
patient
enrol
control
group
studi
approv
beth
israel
deaco
medic
center
committe
clinic
investig
written
consent
studi
personnel
collect
seven
sampl
patient
includ
one
venou
blood
sampl
four
oropharyng
sampl
urin
sampl
fingerstick
blood
sampl
appli
rapid
poc
immunoassay
accord
manufactur
instruct
use
addit
preced
test
subject
suspect
lrti
sputum
blood
cultur
well
chest
xray
particip
subject
requir
one
visit
one
followup
visit
followup
visit
week
initi
visit
necessari
collect
venou
blood
sampl
followup
serolog
test
immunoassay
interpret
identifi
presenc
control
line
result
line
accord
fig
two
oropharyng
sampl
sent
viral
respiratori
pcr
panel
luminex
xtag
austin
tx
viral
pcr
test
wherea
two
oropharyng
sampl
sent
routin
bacteri
cell
cultur
ml
peripher
venou
blood
sampl
collect
purpl
top
tube
ethylenediaminetetraacet
acid
edta
sent
quantit
mxa
immunosorb
assay
elisa
test
use
mxa
protein
elisa
test
kit
kyowa
medex
co
ltd
tokyo
japan
wbc
measur
second
sampl
collect
red
top
tube
use
crp
test
high
sensit
crp
enzym
immunoassay
test
kit
biocheck
inc
foster
citi
ca
diagnosi
chlamydia
pneumonia
mycoplasma
pneumonia
determin
pcr
perform
mean
pair
serolog
time
enrol
week
thereaft
commerci
avail
elisa
test
ani
labsystem
ltd
oy
vantaa
finland
use
accord
manufactur
instruct
detect
immunoglobulin
igm
igg
antibodi
pneumonia
c
pneumonia
atyp
bacteri
infect
confirm
pneumonia
c
pneumonia
identifi
pcr
pneumonia
c
pneumonia
igm
antibodi
detect
twofold
increas
igg
antibodi
acut
convalesc
phase
sampl
found
definit
typic
bacteri
infect
consid
bacterium
cultur
blood
sputum
urin
antigen
assay
legionella
streptococcu
found
posit
subject
suspect
lrti
peripher
venou
blood
collect
sent
plate
routin
bacteri
blood
cultur
upon
reach
clinic
laboratori
specimen
divid
sampl
plate
blood
chocol
agar
specimen
process
within
h
collect
singl
colonyform
unit
cfu
ml
singl
bacteri
speci
indic
infect
colon
expector
sputum
collect
subject
product
cough
presumpt
lrti
sampl
polymorphonuclear
leukocyt
less
squamou
cell
per
microscop
highpow
field
plate
cultur
qualiti
sputum
sampl
evalu
assess
number
inflammatori
epitheli
cell
definit
bacteri
infect
consid
group
beta
hemolyt
strep
growth
occur
bacteri
growth
greater
cfuml
occur
oropharyng
sampl
sputum
sampl
urin
sampl
collect
assay
streptococc
pneumonia
legionella
pneumophila
antigen
immunochromatograph
membran
test
aler
binaxnow
pneumonia
binaxnow
legionella
waltham
perform
urin
sampl
detect
pneumonia
l
pneumophila
antigen
identif
l
pneumophila
pcr
also
confirm
diagnosi
legionella
definit
viral
infect
confirm
oropharyng
pcr
respiratori
panel
luminex
xtag
austin
tx
viral
pcr
posit
viral
nucleic
acid
subject
definit
microbiolog
confirm
diseas
character
accord
algorithm
incorpor
addit
radiolog
laboratori
find
fig
presenc
radiolog
evid
diffus
infiltr
chest
xray
suggest
viral
infect
presenc
radiolog
evid
focal
lobar
process
infiltr
chest
xray
suggest
bacteri
infect
addit
significantli
elev
wbc
count
mm
interpret
suggest
bacteri
infect
two
invalid
test
occur
four
subject
diagnost
indetermin
specimen
leakag
reject
remain
patient
immunoassay
correctli
identifi
subject
neg
infect
ci
confirm
bacteri
infect
ci
confirm
viral
infect
ci
percent
neg
posit
agreement
test
calcul
accord
chart
tabl
enrol
patient
lrti
male
femal
age
rang
mean
age
year
patient
enrol
pharyng
male
femal
age
rang
mean
age
year
viral
pathogen
detect
pcr
includ
influenza
influenza
b
parainfluenza
parainfluenza
three
asymptomat
control
rhinoviru
detect
without
associ
elev
mxa
deem
like
colon
exclud
microbiolog
confirm
viral
bacteri
infect
confirm
microbiolog
character
bacteri
infect
acut
febril
respiratori
infect
frequent
confirm
etiolog
uri
pharyng
lrti
communityacquir
pneumonia
cap
despit
extens
combin
microbiolog
molecular
diagnost
techniqu
includ
molecular
test
bacteri
viral
pathogen
review
recent
scientif
literatur
reveal
numer
prospect
clinic
studi
evalu
etiolog
acut
respiratori
infect
report
failur
pathogen
detect
patient
present
studi
patient
microbi
confirm
infect
patient
without
microbi
confirm
limit
immun
respons
may
repres
potenti
less
signific
clinic
case
muri
rapid
differenti
poc
test
profound
potenti
healthcar
implic
sinc
distinguish
viral
bacteri
infect
clinic
set
shown
challeng
especi
earli
diseas
process
van
gageldonklafeb
et
al
observ
associ
detect
bacteri
viral
pathogen
either
diagnosi
made
gener
practition
subject
report
symptom
moreov
physic
examin
alon
shown
sensit
specif
well
neg
predict
valu
posit
predict
valu
difficulti
establish
etiolog
outpati
diagnosi
acut
febril
respiratori
ill
stem
overlap
symptom
sign
limit
avail
diagnost
test
time
lag
receiv
result
laboratori
test
accord
korppi
crp
measur
recommend
firstlin
method
screen
suspect
bacteri
inflamm
sever
studi
indic
crp
feasibl
accur
differenti
pneumonia
acut
bronchiti
pneumonia
associ
elev
serum
crp
level
greater
mgl
wherea
sever
pneumonia
serum
crp
typic
greater
mgl
scandinavia
poc
crp
test
part
routin
evalu
patient
lrti
use
prove
costeffect
crp
procalcitonin
pct
concentr
use
initi
monitor
antibiot
use
lrti
pct
suggest
monitor
communityacquir
outpati
infect
poc
test
howev
rel
high
cost
make
less
desir
highincid
infect
famili
practic
gener
specif
singl
biomark
term
etiolog
distinct
bacteri
viral
infect
remain
problem
crp
pct
singl
biomark
specif
bacteri
etiolog
infect
high
concentr
lower
concentr
crp
pct
often
observ
viral
bacteri
infect
combin
either
pct
crp
alongsid
mxa
would
help
differenti
viral
bacteri
infect
attempt
panel
test
includ
crp
combin
role
antivir
immun
unsuccess
differenti
viral
bacteri
infect
engelmann
et
al
prospect
examin
children
consist
uninfect
control
confirm
viral
infect
found
mxa
level
uninfect
control
group
significantli
lower
patient
confirm
viral
infect
p
studi
also
found
mxa
level
significantli
lower
patient
confirm
bacteri
infect
patient
confirm
viral
infect
crp
level
higher
patient
confirm
bacteri
infect
confirm
viral
infect
p
use
combin
mxa
crp
indic
infect
roc
curv
sensit
specif
differenti
bacteri
viral
infect
ci
ifn
ifngamma
tnfalpha
cytokin
induc
bacteri
infect
serum
type
ifn
level
remain
within
normal
limit
even
patient
sever
bacteri
infect
substant
data
demonstr
human
infect
respiratori
syncyti
viru
rsv
influenza
b
adenoviru
parainfluenza
viru
metapneumoviru
stimul
robust
cytokin
respons
includ
gamma
interferon
wherea
rhinoviru
typic
stimul
signific
elev
mxa
magnitud
ifn
respons
vari
type
incit
viru
moreov
defici
receptor
ifn
report
increas
sever
respiratori
viral
infect
mxa
found
elev
common
respiratori
viral
infect
well
common
viral
gastrointestin
infect
tabl
high
sensit
pcr
allow
detect
minim
amount
viral
nucleic
acid
clinic
relev
posit
test
result
clear
small
amount
respiratori
viru
could
repres
asymptomat
colon
postinfecti
shed
asymptomat
control
patient
compar
patient
respiratori
ill
pcr
detect
presenc
virus
control
patient
suggest
transient
colon
persist
commonli
associ
rhinoviru
coronaviru
noksokoivisto
show
children
virusposit
sampl
previou
respiratori
symptom
famili
member
concurr
respiratori
symptom
howev
virus
influenza
parainfluenza
metapneumoviru
rsv
rare
detect
asymptomat
subject
present
suggest
activ
infect
sinc
virus
seem
rapidli
clear
respiratori
tract
infect
pcr
suitabl
diagnost
method
determin
infect
rhinoviru
consid
rel
mild
pathogen
colon
nasal
mucosa
without
caus
symptom
rhinoviru
coronaviru
caus
common
cold
typic
caus
invas
infect
fever
immunocompet
host
stimul
ifn
mxa
suggest
causal
infer
base
detect
virus
symptomat
patient
made
caution
accompani
addit
studi
bacteri
infect
confirm
compar
method
deem
bacteri
infect
regardless
presenc
viral
coinfect
univers
accept
method
determin
colon
activ
invas
infect
method
clinic
categor
symptomat
patient
without
definit
microbiolog
confirm
diseas
final
element
tautolog
studi
crp
use
part
compar
method
altern
futur
studi
could
consid
use
pct
surrog
marker
bacteri
infect
despit
limit
interplay
semiquantit
valu
crp
mxa
appear
aid
identif
differenti
infecti
etiolog
warrant
investig
overus
antibiot
import
factor
lead
antibiot
resist
howev
least
antibiot
prescrib
acut
febril
respiratori
infect
need
optim
effect
prescrib
unnecessari
overus
antibiot
associ
increas
antibiot
resist
common
bacteria
advers
reaction
high
cost
entir
healthcar
system
includ
provid
payer
patient
viral
bacteri
infect
contagi
difficult
clinic
differenti
signific
overlap
sign
symptom
difficulti
obtain
relev
specimen
low
sensit
specif
test
use
high
cost
absenc
test
result
within
critic
window
initi
adequ
treatment
often
result
prescript
antibiot
therapi
absenc
bacteri
infect
empir
treatment
especi
preval
young
children
verbal
symptom
outpati
set
access
laboratori
diagnost
limit
independ
antigen
test
cell
cultur
pcr
differenti
activ
invas
infect
bacteri
viral
colon
howev
microbiolog
confirm
presenc
elev
host
immun
respons
indic
clinic
signific
infect
requir
therapeut
intervent
immunecompet
person
pct
crp
ideal
biomark
determin
host
respons
consist
bacteri
confirm
mxa
serv
confirm
presenc
signific
viral
infect
isol
neither
mxa
crp
alon
sensit
specif
identifi
viral
andor
bacteri
infect
howev
multiplex
pattern
result
consist
combin
interpret
low
crp
high
crp
elev
level
mxa
may
provid
sensit
specif
way
identifi
immun
respons
viral
andor
bacteri
infect
use
rapid
test
may
result
lesser
instanc
unnecessari
antibiot
use
reduc
antibiot
resist
lower
healthcar
cost
immunoassay
test
origin
investig
develop
rp
diagnost
rp
clinic
evalu
feasibl
trial
beth
israel
deaco
medic
center
harvard
medic
school
teach
tertiari
care
hospit
studi
design
rp
input
us
food
drug
administr
fda
studi
fund
rp
princip
investig
nathan
shapiro
md
mph
subinvestig
blind
microbi
confirmatori
result
financi
interest
immunoassay
rp
robert
samburski
md
employ
rp
data
collect
process
beth
israel
deaco
medic
center
data
interpret
manuscript
prepar
jointli
beth
israel
deaco
medic
center
rp
laura
lovejoy
saranova
llc
contribut
compens
review
edit
manuscript
